G. S. Falchook

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown et al. · Journal of Clinical Oncology · 2010 · 274 citations

Phase I/ii Study, Mut Braf Melanoma, Immunotherapeutics +20

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment

G. S. Falchook, Francisco Vega, Nam H. Dang et al. · Annals of Oncology · 2009 · 152 citations · Full text

Lymphoid Neoplasia, Hepatology, Histopathology +7

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

J. R. Infante, G. S. Falchook, Donald P. Lawrence et al. · Journal of Clinical Oncology · 2011 · 122 citations

Brafi Exposure, Phase I/ii Study, Immunology +19

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors

David S. Hong, Haby Henary, G. S. Falchook et al. · Investigational New Drugs · 2014 · 90 citations

Tumor Biology, Medicine, Pharmacology +9

Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.

Raoul Tibes, G. S. Falchook, Daniel D. Von Hoff et al. · Journal of Clinical Oncology · 2010 · 42 citations

Immunology, Available Inhibitor, Pharmacotherapy +22